Abstract 289P
Background
Cancer cachexia has been rarely reported in Indonesian BC patients. We aimed to determine the prevalence and factors associated with cancer cachexia following chemotherapy.
Methods
We performed a pre-post observation in 103 BC patients who received chemotherapy and were registered in a prospective study on chemotherapy toxicities in 2018-2020. Most data were abstracted from the main study database, including age, neutrophil-to-lymphocyte ratio, comorbidity, stage, surgery type, chemotherapy information, and the presence of chemotherapy-induced nausea and vomitus. We also analysed vitamin D concentration using ELISA method. Cachexia was defined according to existing criteria from Evans as weight loss of at least 5% or low BMI <20 kg/m2 plus low muscle strength, fatigue, anorexia, low fat-free mass index, or abnormal biochemistry. Multivariate logistic regression test was used to determine factors related to cachexia status following chemotherapy.
Results
Mean age of 103 patients was 52 years (52.5 ± 9.1). All patients had a deficient vitamin D concentration at baseline (median 8.4 ng/mL) and after chemotherapy (median 6.9 ng/mL). At baseline 4.9% of patients (5/103) had cachexia. After chemotherapy 28.2% of patients (29/103) had persistent cachexia or evolved into cachexia. Having persistent cachexia or becoming cachexia was significantly associated with late-stage presentation (OR 3.43, 95%CI 1.10–10.74, p=0.034), receiving >8 chemotherapy cycles (OR 12.05, 95%CI 2.29–63.46, p=0.003) and higher post-chemotherapy vitamin D level (OR 4.60, 95%CI 1.56–13.56, p=0.006). Having a higher baseline vitamin D level was significantly associated with a lower risk of persistent cachexia or evolving into cachexia after chemotherapy (OR 0.33, 95%CI 0.11–0.95, p=0.040).
Conclusions
Cachexia often occurs in local BC patients. Late-stage presentation, receiving >8 chemotherapy cycles and higher post-chemotherapy vitamin D level are associated with an increased risk of cachexia while having a higher baseline vitamin D level is associated with a reduced risk. Strategies and further investigation are warranted to improve cachexia with nutritional support during chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Kementrian Riset, Tekhnologi, dan Pendidikan Tinggi Republik Indonesia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
303P - Long-term oncologic outcomes for patients undergoing volatile versus intravenous anesthesia for non-small cell lung cancer surgery
Presenter: Ji Hyung Hong
Session: Poster viewing 04
306P - Multimodal management and outcomes of stage III non-small cell lung cancer: KINDLE-Egypt analysis
Presenter: Rasha Aboelhassan
Session: Poster viewing 04
307P - Differential expression profiling of transcripts in stage IIIA non-small cell lung cancer (NSCLC) of smokers and non-smokers cases of north India: A geneto-environmental study
Presenter: Archana Mishra
Session: Poster viewing 04
308P - Phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
Presenter: Masanao Nakashima
Session: Poster viewing 04
309P - Pneumonitis and corticosteroid treatment in patients with unresectable non-small cell lung cancer receiving durvalumab consolidation after definitive chemoradiotherapy
Presenter: Saori Murata
Session: Poster viewing 04
311P - Cost-effectiveness of alectinib compared with chemotherapy in first-line treatment for anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer in Thailand
Presenter: Sermsiri Sangroongruangsri
Session: Poster viewing 04
312P - ClinMatch: A clinical trial matching platform that improves trial accessibility among NSCLC patients through comprehensive genomic and clinical profiling
Presenter: Allen Chi Shing Yu
Session: Poster viewing 04
313P - A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpression
Presenter: Yongfeng Yu
Session: Poster viewing 04